LivaNova (NASDAQ:LIVN) Cut to “Buy” at StockNews.com

StockNews.com cut shares of LivaNova (NASDAQ:LIVN) from a strong-buy rating to a buy rating in a report published on Wednesday morning.

Several other equities research analysts also recently issued reports on the stock. Robert W. Baird raised their price objective on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Mizuho dropped their price target on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. Needham & Company LLC reissued a “buy” rating and set a $75.00 target price on shares of LivaNova in a report on Monday, November 25th. Finally, The Goldman Sachs Group began coverage on shares of LivaNova in a research note on Friday, October 4th. They issued a “buy” rating and a $65.00 price target on the stock. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $69.17.

LivaNova Price Performance

NASDAQ:LIVN opened at $46.56 on Wednesday. The firm’s fifty day moving average price is $50.93 and its two-hundred day moving average price is $50.82. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The company has a market cap of $2.53 billion, a P/E ratio of 110.86 and a beta of 0.98. LivaNova has a one year low of $43.15 and a one year high of $64.47.

Insider Buying and Selling

In related news, Director Francesco Bianchi sold 1,250 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the transaction, the director now directly owns 7,522 shares in the company, valued at $383,546.78. This represents a 14.25 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.27% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On LivaNova

Several hedge funds have recently modified their holdings of LIVN. Arizona State Retirement System boosted its stake in shares of LivaNova by 2.0% during the second quarter. Arizona State Retirement System now owns 15,104 shares of the company’s stock valued at $828,000 after purchasing an additional 299 shares in the last quarter. Atria Investments Inc boosted its position in LivaNova by 6.2% during the 3rd quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock worth $297,000 after buying an additional 331 shares during the period. State of Alaska Department of Revenue grew its holdings in LivaNova by 7.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company’s stock worth $328,000 after acquiring an additional 425 shares during the last quarter. Rhumbline Advisers increased its position in LivaNova by 0.4% in the 2nd quarter. Rhumbline Advisers now owns 183,132 shares of the company’s stock valued at $10,039,000 after acquiring an additional 659 shares during the period. Finally, AQR Capital Management LLC raised its stake in shares of LivaNova by 0.7% during the second quarter. AQR Capital Management LLC now owns 129,871 shares of the company’s stock valued at $7,103,000 after acquiring an additional 930 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.